Search Result

Results for "

cyclin B1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CDK (16) Cyclin G-associated Kinase (GAK) (1) 5-HT Receptor (1) Akt (1) APC (2) Apoptosis (13) Aurora Kinase (1) Autophagy (6) Bcl-2 Family (1) c-Myc (1) Caspase (3) Checkpoint Kinase (Chk) (1) DNA/RNA Synthesis (3) Epigenetic Reader Domain (2) ERK (1) GSK-3 (2) HSP (1) JAK (2) JNK (1) Ligands for Target Protein for PROTAC (1) MDM-2/p53 (5) MEK (2) Microtubule/Tubulin (4) Mitosis (1) mTOR (1) p38 MAPK (1) Parasite (2) PKC (1) Polo-like Kinase (PLK) (1) PROTACs (2) Reactive Oxygen Species (ROS) (2) Reference Standards (2) STAT (2) Topoisomerase (1) Wee1 (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (31) Infection (2) Neurological Disease (1)

By Targets:

CDK (16)

Cyclin G-associated Kinase (GAK) (1)

5-HT Receptor (1)

Akt (1)

APC (2)

Apoptosis (13)

Aurora Kinase (1)

Autophagy (6)

Bcl-2 Family (1)

c-Myc (1)

Caspase (3)

Checkpoint Kinase (Chk) (1)

DNA/RNA Synthesis (3)

Epigenetic Reader Domain (2)

ERK (1)

GSK-3 (2)

HSP (1)

JAK (2)

JNK (1)

Ligands for Target Protein for PROTAC (1)

MDM-2/p53 (5)

MEK (2)

Microtubule/Tubulin (4)

Mitosis (1)

mTOR (1)

p38 MAPK (1)

Parasite (2)

PKC (1)

Polo-like Kinase (PLK) (1)

PROTACs (2)

Reactive Oxygen Species (ROS) (2)

Reference Standards (2)

STAT (2)

Topoisomerase (1)

Wee1 (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (31)

Infection (2)

Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Antibodies

Targets Recommended: Cyclin G-associated Kinase (GAK) CDK CDKL

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-B0294

Flubendazole 5+ Cited Publications	Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-12529

Ro-3306 Maximum Cited Publications 52 Publications Verification	CDK Apoptosis	Cancer
Ro-3306 is a potent and selective inhibitor of CDK1, with K_is of 20 nM, 35 nM and 340 nM for CDK1, CDK1/cyclin B1 and CDK2/cyclin E, respectively.

HY-N0417

Cucurbitacin E 5+ Cited Publications α-Elaterin; α-Elaterine	CDK Autophagy	Cancer
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-149261

H1k	Autophagy CDK	Cancer
H1k, a Eudistomin Y derivative, is a lysosome-targeted antiproliferation agent. H1k increases the autophagy signal and downregulate the expression of cyclin-dependent kinase (CDK1) and cyclin B1. H1k can be used in research of cancer .

HY-143660

LG308	Microtubule/Tubulin Apoptosis	Cancer
LG308 is a novel synthetic compound with antimicrotubule activity. LG308 induces mitotic phase arrest and inhibits G2/M progression significantly which is associated with the upregulation of cyclin B1 and mitotic marker MPM-2 and the dephosphorylation of cdc2. LG308 also induces apoptosis and cell death. LG308 significantly suppresses tumor growth. LG308 with antimitotic activity has the potential for the research of prostate cancer .

HY-146817

Tubulin polymerization-IN-11	Microtubule/Tubulin Apoptosis	Cancer
Tubulin polymerization-IN-11 is a potent tubulin polymerization inhibitor with an IC₅₀ value of 3.4 μM. Tubulin polymerization-IN-11 shows antiproliferative activity. Tubulin polymerization-IN-11 induces Apoptosis and cell cycle arrest at G2/M phase. Tubulin polymerization-IN-11 decreases the expression of cyclin B1, p-cdc2, and Bcl-2 protein levels and increases the expression of cleaved PARP .

HY-144637

Autophagy inducer 2	Apoptosis Autophagy	Cancer
Autophagy inducer 2 (Compound 11i) is a potent autophagy inducer. Autophagy inducer 2 exhibits apparent antiproliferative activity against the MCF-7 cell line with an IC₅₀ value of 1.31 μM and remarkably inhibits the colony formation of the MCF-7 cells. Autophagy inducer 2 arrests the MCF-7 cells in the G2/M phase by regulating the cell-cycle-related proteins Cdk-1 and Cyclin B1. Autophagy inducer 2 has the potential for the research of breast cancer .

HY-B0294R

Flubendazole (Standard)	Reference Standards Parasite Microtubule/Tubulin STAT MDM-2/p53 Apoptosis Autophagy	Infection Cancer
Flubendazole (Standard) is the analytical standard of Flubendazole. This product is intended for research and analytical applications. Flubendazole is an anthelmintic drug based on altering microtubule structure, inhibition of tubulin polymerization and disruption of microtubule function. Flubendazole induces apoptosis in human colorectal cancer (CRC) by blocking the STAT3 signaling axis and activation of autophagy. Flubendazole induces P53 expression and reduced Cyclin B1 and p-cdc2 expression. Flubendazole is an antitumor agent. Flubendazole can be used for worm and intestinal parasites .

HY-160643

CDK2-IN-27	CDK	Cancer
CDK2-IN-27 (compound 1) is a potent CDK2 inhibitor with IC₅₀ values of <10, >10-20 nM for CDK2/cyclin E1, CDK2/cyclin B1, respectively .

HY-129727

(E)-MS0019266	DNA/RNA Synthesis Reactive Oxygen Species (ROS) Mitosis	Others
(E)-MS0019266 is a potent inhibitor of DNA damage repair. (E)-MS0019266 inhibits ribonucleotide reductase by generating reactive oxygen species. (E)-MS0019266 also reduces expression of genes related to cell cycle arrest and mitosis, including polo-like kinase 1, kinesin family member 20a, cyclin B1 and aurora kinase A. (E)-MS0019266 is promising for research of inhibitors of ribonucleotide reductase and polo-like kinase 1 .

HY-W781148

Suptopin-2	Topoisomerase	Cancer
Sutopin-2 is a topoisomerase II inhibitor. Suptopin-2 affects cell cycle progression and stability of microtubules. Sutopin-2 induces cell cycle arrest by regulating the nucleocytoplasmic transport of cyclin B1 .

HY-N0417R

Cucurbitacin E (Standard) α-Elaterin (Standard); α-Elaterine (Standard)	Reference Standards CDK Autophagy	Cancer
Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

HY-146095

p53 Activator 2	MDM-2/p53 DNA/RNA Synthesis Apoptosis	Cancer
p53 Activator 2 (compound 10ah) intercalats into DNA and results in significant DNA double-strand break.p53 Activator 2 increases the expression of p53, p-p53, CDK4, p21 to cause cell cycle arrest at G2/M phase.p53 Activator 2 induce apoptosis and significantly down-regulates the anti-apoptosis proteins Bcl-2, Bcl-xL and the levels of cyclin B1.p53 Activator 2 has anti-proliferation activity against MGC-803 cells, with an IC₅₀ of 1.73 µM. p53 Activator 2 displays potent anticancer efficiency against MGC-803 xenograft tumors models .

HY-N2424

Flavone 2-Phenyl-4-chromone	CDK Apoptosis Caspase	Cancer
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21_waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21_waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .

HY-E70653

CDK1/CycB1 Recombinant Human Active Protein Kinase	CDK	Cancer
CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycB1 Recombinant Human Active Protein Kinase is an ortholog of CDK1. CDK1/cyclin B1 complexes initiates mitotic entry by phosphorylating a multitude of proteins to condense chromosomes, disrupt the nuclear envelope, and enable microtubules polymerization to attach and to segregate the chromosomes .

HY-15504A

RGB-286638 free base 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, **cyclin B1-CDK1*, cyclin* E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-15504

RGB-286638 3 Publications Verification	CDK GSK-3 MEK JAK	Cancer
RGB-286638 is a CDK inhibitor that inhibits the kinase activity of cyclin T1-CDK9, **cyclin B1-CDK1*, cyclin* E-CDK2, cyclin D1-CDK4, cyclin E-CDK3, and p35-CDK5 with IC₅₀s of 1, 2, 3, 4, 5 and 5 nM, respectively; also inhibits GSK-3β, TAK1, Jak2 and MEK1, with IC₅₀s of 3, 5, 50, and 54 nM.

HY-176484

CDK9-IN-39	CDK Apoptosis	Cancer
CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC₅₀ of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of RNA polymerase II at Ser2 and can be used for study of colorectal cancer .

HY-150592

Aurora kinase-IN-2	Aurora Kinase	Cancer
Aurora kinase-IN-2 (compound 12Aj) is a potent Aurora kinase inhibitor with IC₅₀ values of 90 and 152 nM for Aurora A and Aurora B. Aurora kinase-IN-2 arrests cell cycle at G2/M phase by regulating cyclin B1 and cdc2. Aurora kinase-IN-2 can be used for cancer research .

HY-119948

AKCI	Cyclin G-associated Kinase (GAK) MDM-2/p53	Cancer
AKCI is a type of AURKC-IκBα interaction inhibitor, with an IC₅₀ value of 24.9 μM. In MDA-MB-231 cells, AKCI can induce G2/M cell cycle arrest by regulating the *p53/p21/CDC2/cyclin* B1** pathway, inhibit cell migration and invasion, and reduce colony formation and tumor growth. AKCI can be used for research on breast cancer .

HY-161521

PLK1-IN-10	Polo-like Kinase (PLK)	Cancer
PLK1-IN-10 (Compound 4Bb) is an orally active PLK1 PBD (polo-box domain) inhibitor. PLK1-IN-10 blocks the interaction of PLK1 with the cell division regulator protein 1 (PRC1) and decreases the protein expression of the CDK1-Cyclin B1 complex. PLK1-IN-10 reacts with glutathione (GSH) to increase cellular oxidative stress, ultimately leading to cell death .

HY-172401

CDC20-IN-2	APC Apoptosis	Cancer
CDC20-IN-2 (14c), a Cdc20 inhibitor (K_D: 7.65 μM), causes G2/M phase arrest and promotes DNA damage accumulation. CDC20-IN-2 (14c) stabilizes key substrates such as Cyclin B1 and Bim, leading to enhanced apoptosis and suppression of tumor cell proliferation and migration .

HY-143327

PROTAC BRD4 Degrader-16	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BRD4 Degrader-16 is a potent PROTAC BRD4 Degrader, with IC₅₀ values of 34.58 nM (BRD4 (BD1)) and 40.23 nM (BRD4 (BD2)). PROTAC BRD4 Degrader-16 ignificantly attenuates G2/M progression associated Cyclin B1 expression. PROTAC BRD4 Degrader-16 significantly induces apoptosis in MV-4-11 cells .

HY-161857

Akt/mTOR-IN-1	Akt mTOR Caspase CDK	Cancer
Akt/mTOR-IN-1 (Compound 8r) is an AKT/mTOR signaling pathway inhibitor exhibiting an IC₅₀ value of 0.8 µM with anticancer activity. Akt/mTOR-IN-1 can decrease the expression of Caspase 3 and increase the expression of the autophagic protein Cyclin B1, thereby inducing cell autophagy and apoptosis. Akt/mTOR-IN-1 can be used in research related to non-small cell lung cancer (NSCLC) .

HY-161826

Antitumor agent-174	Wnt β-catenin HSP CDK c-Myc	Cancer
Antitumor agent-174 (Compound 10) directly engages the N-terminal site of Hsp90 and promotes the degradation of β-catenin, thereby suppressing the Wnt/β-catenin signaling. Antitumor agent-174 effectively inhibits proliferation, induce S and G2/M phases arrest and block the clonogenic ability in CRC cells. Antitumor agent-174 down-regulates CDK1, Cyclin D1, c-Myc, Cyclin B1, and Cyclin A2, and upregulaties P21 proteins. Antitumor agent-174 has significant anti-tumor efficacy against colorectal cancer (CRC) with excellent pharmacokinetics and low toxicity .

HY-143328

PROTAC BRD4 Degrader-17	PROTACs Epigenetic Reader Domain Apoptosis	Cancer
PROTAC BRD4 Degrader-17 (compound 13i) is a potent PROTAC BRD4 Degrader, with IC₅₀ values of 29.54 nM (BRD4 (BD1)) and 3.82 nM (BRD4 (BD2)). PROTAC BRD4 Degrader-17 significantly attenuates G2/M progression associated Cyclin B1 expression. PROTAC BRD4 Degrader-17 significantly induces apoptosis in MV-4-11 cells .

HY-175261

DHI1	CDK Wee1 Checkpoint Kinase (Chk)	Cancer
DHI1 is an anti-leukemia agent with high selectivity for Jurkat (IC₅₀ = 21.83 μM) and HL-60 (IC₅₀ = 19.14 μM) leukemia cells and has low toxicity to non-cancerous cells. DHI1 can induce G2/M phase cell arrest in Jurkat and HL-60 leukemia cells, as well as S phase arrest in HL-60 cells, and has significant effects on cell cycle signaling molecules Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasion of Jurkat and HL-60 cells by disrupting cytoskeletal actin filaments. DHI1 can be used to study hematological malignancies .

HY-170965

Anticancer agent 264	CDK DNA/RNA Synthesis	Cancer
Anticancer agent 264 (Compound 5w) is an anticancer agent that exhibits significant antiproliferative activity across tumor cell lines, with an IC₅₀ range of 7.5-33.67 μM. Anticancer agent 264 significantly induces G2/M phase arrest in MDA-MB-231, MIA PaCa-2, and DU-145 cell lines. Anticancer agent 264 reduces the expression of key cell cycle proteins, including CDK1, CDK2, and Cyclin B1, in a dose-dependent manner, and shows strong binding affinity with inhibitor of differentiation (ID) proteins and DNA-binding proteins. Anticancer agent 264 can be used for research in the field of cancer-related diseases .

HY-130841

Apcin-A	APC Ligands for Target Protein for PROTAC	Cancer
Apcin-A is a small molecule inhibitor that selectively targets the cell division cycle protein Cdc20 and is a derivative of Apcin (HY-110287). Apcin-A competitively binds to the D-box binding pocket of Cdc20 and inhibits substrate ubiquitination mediated by the anaphase promoting complex APC/C-Cdc20. Apcin-A also blocks the binding of Cdc20 to substrates (such as securin and cyclin B1), inhibiting anaphase initiation and cell cycle exit. Apcin-A can promote or prolong mitotic slippage in coordination with p31 ^comet under conditions of high spindle assembly checkpoint (SAC) activity. Apcin-A can be used to develop anti-mitotic drugs and overcome tumor chemotherapy resistance. Apcin-A can be used to synthesize PROTAC CP5V (HY-130257)[1][2][3].

HY-169412

MAPK-IN-3	MDM-2/p53 CDK Caspase Bcl-2 Family Reactive Oxygen Species (ROS) p38 MAPK ERK JNK	Cancer
MAPK-IN-3 (Compound 4a) is an anti-proliferative agent that shows particularly strong inhibitory effects on KYSE 30, HCT 116, and HGC 27, with IC₅₀ values of 0.57 μM, 3.27 μM, and 2.28 μM, respectively. MAPK-IN-3 blocks the cell cycle via a p53-dependent mechanism and induces cell apoptosis through a p53-independent mechanism. MAPK-IN-3 downregulates the expression of cell cycle-related proteins like Cyclin D1 and cyclin B1, upregulates pro-apoptotic proteins such as cleaved PARP, cleaved caspase-7, and cleaved caspase-9, and reduces the expression of anti-apoptotic proteins like Bcl-2. Additionally, MAPK-IN-3 increases the intracellular level of ROS in KYSE 30 cells and upregulates the expression of members of the MAPK signaling pathway associated with ROS, such as p-ERK, p-p38 and p-JNK .

HY-103118

PU02	5-HT Receptor Apoptosis	Neurological Disease Cancer
PU02, a derivative of 6-MP (HY-13677), is a negative allosteric modulator (NAM) of 5-HT₃ receptor, with IC₅₀ values of 0.36 and 0.73 μM in HEK293 cells transfected with human 5-HT₃A and 5-HT₃AB receptors respectively .

HY-11009

CGP60474 5+ Cited Publications	CDK PKC	Cancer
CGP60474, a highly potent anti-endotoxemic agent, is a potent cyclin-dependent kinase (CDK) inhibitor (IC₅₀ values are 26, 3, 4, 216, 10, 200 and 13 nM for CDK1/B, CDK2/E, CDK2/A, CDK4/D, CDK5/p25, CDK7/H and CDK9/T, respectively). CGP60474 is a selective and ATP-competitive PKC inhibitor .

Cucurbitacin E 5+ Cited Publications α-Elaterin; α-Elaterine	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Cancer	CDK Autophagy
Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

Flavone 2-Phenyl-4-chromone	Structural Classification Flavonoids Classification of Application Fields Flavones Source classification Metabolic Disease Endogenous metabolite Disease Research Fields	CDK Apoptosis Caspase
Flavone is an anti-tumor compound that targets cell cycle regulatory proteins (such as cyclin B1) and apoptosis-related factors (such as p21_waf1, PIG3). Flavone selectively induces mitochondrial-mediated apoptosis pathways in tumor cells, inhibits cyclin B1 protein expression, upregulates p21_waf1, and activates p63/p73 proteins. Flavone has immunomodulatory functions that enhance natural killer cell (NK cell) activity and lymphocyte proliferation. Flavone is used in cancer research, especially for its inhibitory potential in solid tumor models such as esophageal cancer and liver cancer .

Cucurbitacin E (Standard) α-Elaterin (Standard); α-Elaterine (Standard)	Triterpenes Structural Classification Terpenoids Source classification Cucurbitaceae Plants	Reference Standards CDK Autophagy
Cucurbitacin E (Standard) is the analytical standard of Cucurbitacin E. This product is intended for research and analytical applications. Cucurbitacin E is a natural compound which from Cucurbitaceae plants. Cucurbitacin E significantly suppresses the activity of the cyclin B1/CDC2 complex.

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80097

	Cyclin B1 Antibody (YA486)	WB, ICC/IF, IHC-P, IP	Human
	Cyclin B1 Antibody (YA486) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Cyclin B1.

HY-P80632

	Cyclin B1 Antibody CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IHC-F, IHC-P, ICC/IF, ELISA	Human, Mouse, Rat
	Cyclin B1 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to Cyclin B1.

HY-P84097

	Cyclin B1 Antibody (YA3794) CCNB; CCNB1	WB, ICC/IF, FC, ELISA	Human, Rat
	Cyclin B1 Antibody (YA3794) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to Cyclin B1.

HY-P80806

	*Phospho-Cyclin* B1 (Ser126) Antibody (YA208)** CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IP	Human
	Phospho-Cyclin B1 (Ser126) Antibody (YA208) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cyclin B1 (Ser126).

HY-P85113

	Cyclin B1 Antibody (YA4805) CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IP, ICC/IF, FC, ELISA	Human, Rat
	Cyclin B1 Antibody (YA4805) is a Mouse-derived and non-conjugated monoclonal antibody, targeting to Cyclin B1.

HY-P86525

	*Phospho-Cyclin* B1(Ser126) Antibody (YA6217)** CCNB1; CCNB; G2/mitotic-specific cyclin-B1	WB, IHC-P, ICC/IF, IP, ELISA	Human
	Phospho-Cyclin B1(Ser126) Antibody (YA6217) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Cyclin B1(Ser126).

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks